Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
1992 1
2003 1
2004 1
2005 1
2006 2
2008 2
2009 1
2010 1
2013 1
2017 2
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G. Denis F, et al. J Clin Oncol. 2004 Jan 1;22(1):69-76. doi: 10.1200/JCO.2004.08.021. Epub 2003 Dec 2. J Clin Oncol. 2004. PMID: 14657228 Clinical Trial.
PURPOSE: We report the 5-year survival and late toxicity results of a randomized clinical trial, which showed a 3-year improvement in overall survival and locoregional control of stage III or IV oropharynx carcinoma, using concomitant radiochemotherapy (arm B …
PURPOSE: We report the 5-year survival and late toxicity results of a randomized clinical trial, which showed a 3-year improvement in …
Revisiting induction chemotherapy for head and neck cancer.
Argiris A, Jayaram P, Pichardo D. Argiris A, et al. Oncology (Williston Park). 2005 May;19(6):759-70. Oncology (Williston Park). 2005. PMID: 15971451 Free article. Review.
As interest in induction regimens is renewed, we elected to conduct a systematic review of trials of induction chemotherapy for locoregionally advanced head and neck cancer. ...In a meta-analysis, induction with platinum/ …
As interest in induction regimens is renewed, we elected to conduct a systematic review of trials of induction chemotherapy fo …
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Burgy M, Leblanc J, Borel C. Burgy M, et al. Anticancer Drugs. 2018 Apr;29(4):287-294. doi: 10.1097/CAD.0000000000000595. Anticancer Drugs. 2018. PMID: 29420335 Review.
The issue of induction chemotherapy (ICT) interest in locoregionally advanced squamous cell cancer of the head and neck is a real epic that has been carried out over four phase III studies: PARADIGM, DECIDE, NCT01086826 and lastly the conclusive …
The issue of induction chemotherapy (ICT) interest in locoregionally advanced squamous cell cancer of the head a …
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Haddad RI, et al. Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549. Ann Oncol. 2019. PMID: 30596812 Free PMC article. Clinical Trial.
BACKGROUND: The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). ...PATIENTS AND METHODS: Eligible patients were 18 …
BACKGROUND: The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally …
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB. Specenier PM, et al. Ann Oncol. 2017 Sep 1;28(9):2219-2224. doi: 10.1093/annonc/mdx300. Ann Oncol. 2017. PMID: 28911062 Free article. Clinical Trial.
BACKGROUND: Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior induction chemotherapy. METHODS: Patients with stage III/IV unresectable, squamous cell carcinoma of the head and neck rece …
BACKGROUND: Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior indu …
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Tao Y, Aupérin A, Graff P, Lapeyre M, Grégoire V, Maingon P, Geoffrois L, Verrelle P, Calais G, Gery B, Martin L, Alfonsi M, Deprez P, Bardet E, Pignon T, Rives M, Sire C, Bourhis J. Tao Y, et al. Oral Oncol. 2017 Aug;71:61-66. doi: 10.1016/j.oraloncology.2017.06.002. Epub 2017 Jun 9. Oral Oncol. 2017. PMID: 28688693 Clinical Trial.
Patients received either VART: 64.8Gy/3.5weeks or one of the 3 following CRT regimens: Conventional CRT: 70Gy/7weeks+3 cycles carboplatin-5FU; Moderately accelerated CRT: 70Gy/6weeks+2 cycles carboplatin-5FU; Strongly intensified CRT: 64Gy/5weeks+cispl …
Patients received either VART: 64.8Gy/3.5weeks or one of the 3 following CRT regimens: Conventional CRT: 70Gy/7weeks+3 cycles carboplatin …
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, Sickafuse S, Keegan P, Pazdur R. Cohen MH, et al. Oncologist. 2013;18(4):460-6. doi: 10.1634/theoncologist.2012-0458. Epub 2013 Apr 10. Oncologist. 2013. PMID: 23576486 Free PMC article.
Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Approva …
Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first- …
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA, Natale RB, Takasugi BJ, Goren MP, Vogel WC, Kudla-Hatch V. Forastiere AA, et al. J Clin Oncol. 1987 Feb;5(2):190-6. doi: 10.1200/JCO.1987.5.2.190. J Clin Oncol. 1987. PMID: 3543242
Twenty-nine patients with recurrent or advanced, incurable head and neck cancer were entered into a phase I-II trial of carboplatin in combination with 5-fluorouracil (5-FU), 1,000 mg/m2/d continuous intravenous (IV) infusion for f …
Twenty-nine patients with recurrent or advanced, incurable head and neck cancer were entered into a phase I-II trial of …
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB. Mesía R, et al. Ann Oncol. 2010 Oct;21(10):1967-1973. doi: 10.1093/annonc/mdq077. Epub 2010 Mar 24. Ann Oncol. 2010. PMID: 20335368 Free PMC article. Clinical Trial.
BACKGROUND: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and …
BACKGROUND: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based ch …
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE. Salama JK, et al. Ann Oncol. 2008 Oct;19(10):1787-94. doi: 10.1093/annonc/mdn364. Epub 2008 Jun 6. Ann Oncol. 2008. PMID: 18539617 Free article. Clinical Trial.
BACKGROUND: We hypothesized induction chemotherapy (IndCT) would improve distant control (DC) without compromising locoregional control (LRC) for locoregionally advanced head and neck cancer patients. Additionally, we systematically lowered radi …
BACKGROUND: We hypothesized induction chemotherapy (IndCT) would improve distant control (DC) without compromising locoregional contr …
16 results